Abstract
Interleukin-l0 (IL-10) has multiple in vitro actions on different cell types including thymocytes,1 T and B lymphocytes,2–4 monocytes,5 neu-trophils,6 and mast cells.7 When cultured with T lymphocytes, IL-10 suppresses IL-2 and IFN-γ production and inhibits mitogen-induced T-cell proliferation.8,9 On the other hand, IL-10 stimulates B-cell growth and immunoglobulin (Ig) production.4 In monocytes, IL-10 inhibits synthesis and gene expression for IL-1, TNF, IL-6, IL-8, and colony stimulating factors.5,8 Similar effects have been observed in neutrophils.6 IL-10 also prevents macrophage cytotoxic activity by inhibiting both cytokine and nitric oxide production.10
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
MacNeil IA, Suda T, Moore KW et al. IL-10, a novel growth cofactor for mature and immature T cells. J Immunol 1989; 145: 4167–73.
Del Prete G, De Carli M, Almerigogna F et al. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 1993; 150: 353–60.
Fiorentino DF, Zlotnik A, Vieira P et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by TH1 cells. J Immunol 1991; 146: 3444–51.
Rousset F, Garcia E, Defrance T et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992; 89: 1890–93.
Waal Malefyt R, Abrams J, Bennett B et al. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209–20.
Cassatella MA, Meda L, Bonora S et al. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1ß in mediating the production of IL-18 triggered by lipopolysaccharide. J Exp Med 1993; 178: 2207–11.
Thompson-Snipes L, Dhar V, Bond W et al. Interleukin 10: A novel stimulatory factor for mast cells and their progenitors. J Exp Med 1991; 173: 507–10.
Vieira P, De Waal Malefyt R, Dang MN et al. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: Homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci USA 1991; 88: 1172–76.
Taga K, Tosato G. IL-10 inhibits T cell proliferation and IL-2 production. J Immunol 1992; 148: 1143–48.
Bogdan C, Vodovotz Y Nathan C. Macrophage deactivation by IL-10. J Exp Med 1991; 174: 1549–55.
Bean AGD, Freiberg RA, Andrade S et al. Interleukin 10 protects mice against staphylococcal enterotoxin B-induced lethal shock. Infect Immun 1993; 61: 4937–39.
Gerard C, Bruyns C, Marchant A et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993; 177: 547–50.
Howard M, Muchamuel T, Andrade S et al. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 1993; 177: 1205–8.
Kuhn R, Lohler J, Rennick D et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263–74.
Ishida H. Clinical implications of IL-10 in patients with immune and inflammatory diseases. Lymphokine Cytokine Res (abstr) 1993; 12: 344.
Bacchetta R, Bigler M, Touraine J et al. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med 1994; 179: 493–502.
Lisi PJ, Chu CW, Koch, GA et al. Development and use of a radioimmunoassay for human interleukin 1B. Lymphokine Res 1987; 7: 75–84.
van der Meer JWM, Endres S, Lonnemann G et al. Concentrations of immunoreactive human tumor necrosis factor-a produced by human mononuclear cells in vitro. J Leukoc Biol 1988; 43: 216–23.
Schindler R, Mancilla J, Endres S et al. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990; 75: 40–47.
Porat R, Poutsiaka DD, Miller LC et al. Interleukin-1 (IL-1) receptor blockade reduces endotoxin and Borrelia burgdorferistimulated IL-8 synthesis in human mononuclear cells. FASEB J 1992; 6: 2482–2486.
Poutsiaka DD, Clark BD, Vannier E et al. Production of interleukin-1 receptor antagonist and interleukin-10 by peripheral blood mononuclear cells is differentially regulated. Blood 1991; 78: 1275–81.
Zielen S, Bauscher P, Hofmann D et al. Interleukin 10 and immune restoration in common variable immunodeficiency [letter]. Lancet 1993; 342: 750–1.
Sironi M, Munoz C, Pollicino T et al. Divergent effects of Interleukin-10 on cytokine production by mononuclear phagocytes and endothelial cells. Eur J Immunol 1993; 23: 2692–95.
Helle M, Brakenhoff JP, De GER et al. Interleukin 6 is involved in Interleukin 1-induced activities. Eur J Immunol 1988; 18: 957–59.
Hirano T, Taga T, Nakano N et al. Purification to homogeneity and characterization of human B cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci USA 1985; 82: 5490–94.
Gauldie J, Richards C, Harnish D et al. Interferon 02/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987; 84: 7251–55.
Kawano M, Hirano T Matsuda T, Taga T et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332: 83–5.
Nordan RP, Potter M. A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. Science 1986; 233: 566–69.
Houssiau FA, Devogelaer J-P, Van Damme J et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988; 31: 784–88.
Hirano T, Taga T, Kiyoshi Y et al. Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc Natl Acad Sci USA 1987; 84: 228–31.
Yoshizaki K, Matsuda T, Nishimoto N et al. Pathological significance of interleukin 6 (IL-6/BSF2) in Castelman’s’ disease. Blood 1989; 74: 1360–67.
Beck JT, Hsu S, Wijdenes J et al. Brief report: Alleviation of systemic manifestations of Castelman’s disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994; 330: 602–05.
Rights and permissions
Copyright information
© 1995 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Chernoff, A.E. et al. (1995). A Phase I Study of Interleukin-10 in Healthy Humans: Safety and Effects on Cytokine Production. In: Interleukin-10. Molecular Biology Intelligence Unit. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-22038-2_17
Download citation
DOI: https://doi.org/10.1007/978-3-662-22038-2_17
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-22040-5
Online ISBN: 978-3-662-22038-2
eBook Packages: Springer Book Archive